Cash runway into Q3 2026AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer's BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025. "The first quarter of 2025 marked steady progress across our pipeline," said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. "Our lead i

Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210US $15M milestone payment from Merck extends company's cash runway to Q3 2026Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is planned to follow the read-out of the Phase 3 study in social anxiety disorder SAD. BURLINGTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) ("Neuphoria" or the

BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) (Neuphoria or Company), "), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025. Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer will be joined by Neuphoria's board of directors, members of the management team, and advisors. "We are honored to ring the Nasdaq Opening Bell to celebrate our successful redomiciliation to the US and the la

BURLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) (Neuphoria or Company), a late-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that the Company is due to receive a $15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia (NCT06

4/A - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)

10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)

NT 10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)

10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)

424B5 - Neuphoria Therapeutics Inc. (0001191070) (Filer)

424B5 - Neuphoria Therapeutics Inc. (0001191070) (Filer)

EFFECT - Neuphoria Therapeutics Inc. (0001191070) (Filer)

S-8 - Neuphoria Therapeutics Inc. (0001191070) (Filer)

S-3 - Neuphoria Therapeutics Inc. (0001191070) (Filer)

8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)